Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5)

Şenocak Taşçı, ElifOyan, BaşakSönmez, ÖzlemMutlu, Arda UlaşAtcı, Muhammed MustafaSakin, AbdullahÖner, İremYeşil Çınkır, HavvaKarakurt Eryılmaz, MelekÇağlayan, DilekYazdan Balçık, OnurPaksoy, NailBozkurt, Mustafa2024-02-022024-02-022024Şenocak Taşçı, E., Oyan, B., Sönmez, Ö., Mutlu, A. U., Atcı, M. M., Sakin, A. ... Bozkurt, M. (2024). Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5). BMC Cancer, 24(1). https://dx.doi.org/10.1186/s12885-024-11863-01471-2407https://dx.doi.org/10.1186/s12885-024-11863-0https://hdl.handle.net/20.500.12511/12240Following publication of the original article [1], the authors reported an error in the affiliations of authors Başak Oyan, Özlem Sönmez, Leyla Özer, Ali Arıcan, Özlem Er and Mustafa Bozkurt. These authors are all affiliated to institution 2.enAttribution 4.0 Internationalinfo:eu-repo/semantics/openAccessColon CancerFluouracilRechallengeRegorafenibSurvivalThird-Line TreatmentCorrection: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5)Other24110.1186/s12885-024-11863-02-s2.0-8518282880738166764Q1